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ABSTRACT 
 
Background: Rapid and effective diagnosis of multidrug-resistant tuberculosis (MDR-TB) is an essential 
component of global tuberculosis control, but most MDR-TB cases are still not diagnosed. 
 
Objective: To assess if patient sputum bacterial load can be used to identify patients that are at higher risk of 
having multidrug resistant TB. 
 
Methods: We used a case-control study and multivariable logistic regression models to investigate associations 
between MDR-TB and sputum bacterial load, as measured by semi-quantitative microscopy and automated time 
to detection of liquid culture. We assessed data from retreatment TB patients with MDR-TB (cases) and without 
MDR-TB (controls) at a reference laboratory in Cameroon.  
 
 
Results: MDR-TB was associated with a smear microscopy grade of 3+ (odds ratio, 21.9; 95% confidence 
interval [CI] 6.2-76.8) or 2+ (odds ratio, 10.8; 95% CI 2.9-40.7), as compared to a result of 1+, scanty or smear-
negative, among 80 MDR-TB cases and 521 controls. MDR-TB was associated with automated time to detection 
of ≤160 hours (odds ratio, 2.2; 95% CI, 1.1-4.7) as compared to >160 hours among a sub-population of 47 cases 
and 350 controls. 
 
Conclusions: A higher sputum bacterial load is associated with MDR-TB in retreatment patients in Cameroon.  
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INTRODUCTION 1 
 2 
The increasing prevalence of multidrug-resistant tuberculosis (MDR-TB)  has exacerbated the ongoing public 3 
health challenge of tuberculosis control.1 In spite of significant increases in the detection of MDR-TB in recent 4 
years, global control efforts are still limited by insufficient laboratory testing capacity; in 2013, only 28% of the 5 
480,000 estimated incident MDR-TB cases were diagnosed worldwide. 2 Improvements in screening methods to 6 
identify the patients most at-risk of MDR-TB may help to increase testing efficiency and reduce time to 7 
diagnosis of MDR-TB cases. Better and faster diagnosis, combined with initiation on appropriate treatment, will 8 
also help to reduce disease transmission. 9 
 10 
Previous TB treatment is the most significant known risk factor for MDR-TB, and the prevalence of MDR-TB 11 
also varies significantly by geographical region.3 The development of drug resistance by drug selection pressure 12 
may be related to several factors, including drug supply and quality of care.4 In addition, a significant amount of 13 
evidence now indicates that both patient and bacteria-specific variables are important contributors to the 14 
development of drug resistance. 5–8  15 
Genetically-based drug resistance in Mycobacterium tuberculosis occurs exclusively as a result of chromosomal 16 
mutations, and recent studies indicate that the rate at which these bacteria acquire drug-resistant mutations may 17 
be much higher than previously estimated. 9–12 Importantly, models developed to predict the evolution of MDR-18 
TB in vivo reveal that patients with higher bacterial burdens, who have correspondingly more potential for drug-19 
resistant mutations to be present, are at greater risk to develop MDR-TB than patients who have lower bacterial 20 
burdens. 9,10 21 
Clinically, more severe pulmonary tuberculosis disease is characterized by an increase in the amount of lung area 22 
involved, density of lesions, and cavitation apparent on chest x-ray, which is associated with higher rates of 23 
smear-positivity for acid-fast bacilli 13 and reduced time to detection in culture. 14 24 
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By integrating the prediction that patients with higher bacterial burdens are more likely to develop MDR-TB, 25 
with evidence that pulmonary TB patients with more severe disease produce larger numbers of bacteria in their 26 
sputum, we aimed to determine whether patients with higher sputum bacterial loads are more likely to be MDR-27 
TB cases. We assessed this using a case-control study of archival data from a TB reference laboratory in 28 
Cameroon. 29 
 30 
STUDY POPULATION AND METHODS 31 
 32 
Study population and setting 33 
The study population consisted of patients from whom sputum specimens were received at the Tuberculosis 34 
Reference Laboratory Bamenda in Cameroon for drug susceptibility testing (DST). The lab serves four regions 35 
of the country, representing a total population of ~7.8 million people. The National TB Program (NTP) 36 
guidelines recommend DST for all previously treated cases of TB, including those classified as relapses, 37 
treatment after loss to follow-up, and treatment after failure, following WHO case definitions.2 DST coverage for 38 
the four regions during 2012 and 2013 was estimated from NTP data as 67% of smear-positive retreatment 39 
patients; estimating the coverage of smear-negative retreatment patients is not possible from this data but is 40 
likely much lower since only ~7% of specimens received for DST during this period were smear negative. In 41 
line with WHO recommendations,15 the NTP uses a standard 6-month rifampin-throughout regimen for new 42 
cases, and a standard 8-month regimen for retreatment cases.  43 
 44 
 Study Design 45 
This was an unmatched case control study of archived routine laboratory data. Two case definitions were used. 46 
In the main analysis, case patients were defined as those with TB bacilli resistant to both isoniazid and rifampin, 47 
and control patients were those with TB bacilli susceptible to both or monoresistant to one of the drugs. In the 48 
secondary case definition, cases were defined as those with TB bacilli resistant to rifampin and controls were 49 
those with bacilli susceptible to rifampin. Both case definitions have clinical and diagnostic value; current World 50 
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Health Organization (WHO) guidelines recommend that patients with rifampin-resistant TB (RR-TB) are 51 
eligible for MDR-TB treatment.16  Specimens received from June 15, 2012 to September 30, 2013 were included 52 
in the analysis. The study was approved by the National Ethics Committee of Cameroon. 53 
 54 
Laboratory procedures 55 
Sputum specimens were processed using the N-acetyl-L-cysteine–NaOH (NALC-NaOH) method.17 From the re-56 
suspended pellet, a concentrated smear was prepared and examined for acid-fast bacilli by fluorescence 57 
microscopy, 0.5mL was cultured on mycobacterial growth indicator tubes (MGIT) using the BACTEC MGIT 58 
960 system, and ~0.1mL was cultured on Löwenstein-Jensen media. Rapid molecular DST for isoniazid and 59 
rifampin resistance was performed using the Genotype MTBDRplus line probe assay according to the 60 
manufacturer’s instructions. Smear-positive specimens were processed and tested directly by the MTBDRplus 61 
assay 18. Smear-negative, culture-positive specimens were tested for M. tuberculosis complex by MPT64 antigen 62 
detection (Standard Diagnostics, Korea), and if positive, then tested by MTBDRplus assay. Following WHO 63 
guidelines, any specimen with any resistance on the rapid assay was also tested using the proportion method on 64 
Löwenstein-Jensen media for isoniazid and/or rifampin resistance, with critical concentrations of 0.2mg/L and 65 
40mg/L respectively. 19,20 Resistance for isoniazid or rifampin by either the MTBDRplus assay or the phenotypic 66 
proportion method was considered as resistant; 21 no specimens that were resistant by rapid testing were 67 
sensitive by phenotypic testing (Supplementary Figure 1). The laboratory participates in annual external quality 68 
assurance for DST under the WHO global project for TB drug resistance surveillance with excellent results. 69 
  70 
Description of variables 71 
 72 
Patients: As shown in Figure 1, during the study period the laboratory received sputum specimens from 739 73 
retreatment patients that were smear and/or culture positive for acid-fast bacilli; of these, specimens from 665 74 
patients were confirmed to be positive for Mycobacterium tuberculosis complex and had interpretable DST 75 
results. Among these, 601 patients (90.2%) had known TB treatment history, sex and age; 397 of these (66.1%) 76 
also had results for automated liquid culture time to detection.  77 
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Laboratory results: Patients who had at least one specimen positive for Mycobacterium tuberculosis complex 78 
by Genotype MTBDRplus assay and/or proportion method DST were considered to have TB. Microscopy 79 
results were obtained on the same day as specimen processing, which was before the DST results were available. 80 
Smears were graded semi-quantitatively according to the IUATLD/WHO scale for fluorescence microscopy and 81 
categorized as 3+, 2+ or 1+/scanty/negative. The automated liquid culture (BD MGIT 960) instrument records 82 
the time to detection (TTD) of culture positivity in hours; this variable corresponds to the number of colony-83 
forming units (CFU) per milliliter and therefore provides a measure of the density of viable bacilli in the sputum. 84 
22,23  85 
 86 
Data extraction and statistical analysis 87 
Patients for inclusion in the analysis were identified from the electronic laboratory database, and patient 88 
information and specimen results were verified against the paper laboratory registers. Univariable and 89 
multivariable logistic-regression models were used to estimate odds ratios and the associated 95% confidence 90 
intervals. Age, sex and any variables that were found to be significant in the univariable analysis were included 91 
in the multivariable analysis, as indicated for each analysis. Epidata Analysis (v. 2.2), and Stata (v. 9.2) software 92 
were used for all analyses. The STROBE recommendations were followed for reporting these data.24 93 
 94 
RESULTS 95 
In the multivariable analysis of 80 cases and 521 controls (Table 2), MDR-TB was associated with a smear 96 
microscopy grade of 3+ (odds ratio, 21.9; 95% CI 6.2-76.8) or 2+ (odds ratio, 10.8; 95% CI, 2.9-40.7), treatment 97 
failure (odds ratio, 10.2; 95% CI, 5.4-19.2), and originating from the Southwest region (odds ratio, 6.4; 95% CI, 98 
2.2-18.9).  The distribution of MDR-TB cases as compared to non-MDR-TB controls is shown as a function of 99 
smear microscopy grade and type of retreatment case in Figure 2. 100 
 101 
The multivariable analysis revealed an association between higher smear microscopy grade and MDR-TB that 102 
was independent of whether the patient was categorized as failure of treatment. To further explore the 103 
association between sputum bacterial load and MDR-TB among patients not on treatment at the start of the 104 
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retreatment regimen, we performed a separate analysis including only relapse and return after default patients 105 
and excluding treatment failures. In the multivariable analysis of these 48 cases and 469 controls, MDR-TB was 106 
associated with a smear microscopy grade of 3+ (odds ratio, 21.4; 95% CI, 2.9-160) or 2+ (odds ratio, 9.7; 95% 107 
CI, 1.2-79.8) and originating from the Southwest region (Supplementary Table 2). 108 
 109 
When any rifampin-resistance rather than resistance to both isoniazid and rifampin was used as a case definition, 110 
there were 92 cases and 509 controls. In the multivariable analysis, rifampin-resistant TB was associated with a 111 
smear microscopy grade of 3+ (odds ratio, 11.9; 95% CI 4.7-30.4) or 2+ (odds ratio, 5.1; 95% CI, 1.8-14.2), 112 
treatment failure, originating from the Southwest, and being female (odds ratio, 1.8; 95% CI, 1.1-3.0), 113 
(Supplementary Table 3). 114 
 115 
For the sub-population of patients with specimens that also had data on time to detection of liquid culture, 116 
including 47 cases and 350 controls, the median time to detection for MDR-TB cases was 139 hours 117 
(interquartile range [IQR], 106- 190), while for non-MDR-TB controls the median time to detection was 166 118 
hours (IQR, 116-236). In the multivariable analysis, MDR-TB was associated with a time to detection result of 119 
≤160 hours (odds ratio, 2.2; 95% CI, 1.1-4.7) and treatment failure, as shown in Table 3. 120 
 121 
DISCUSSION 122 
In this study of tuberculosis retreatment patients in Cameroon, we found an association between multidrug-123 
resistant TB and higher sputum bacterial load, as assessed by both semi-quantitative sputum microscopy of acid-124 
fast bacilli and automated time to detection of culture. An association between higher smear microscopy grade 125 
and rifampin-resistant TB was also observed; this finding is important since rifampin-resistance is frequently 126 
used as a surrogate for rapid diagnosis of multidrug-resistant TB.25  These results are consistent with previous 127 
reports of an association between MDR-TB and smear-positivity as compared to smear-negativity at baseline 128 
diagnosis26,27  and a report of higher numbers of MDR-TB patients among patients with higher microscopy 129 
smear grades;28 these results are also consistent with previous reports of an association between cavitary disease 130 
and MDR-TB since cavitary pulmonary TB is associated with higher sputum bacterial load.29,30  131 
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This work was motivated by predictions that higher patient bacterial load is associated with multidrug 132 
resistance9,10 and evidence that higher patient bacterial load corresponds to higher sputum bacterial load.13,14 133 
However, the relationship between patient bacterial load and sputum bacterial load in pulmonary TB is not 134 
simple; it depends on several factors, including patient comorbidities and physiology. For example, patients that 135 
are severely immunocompromised are more likely to have disseminated TB with fewer TB bacilli in their 136 
sputum; 31,32 in addition, in many patients highly smear-positive TB does not emerge predictably over time but 137 
instead develops quickly. 33 Similarly, the relationship between sputum bacterial load and drug resistance may 138 
depend on a range of factors, including setting-specific MDR-TB prevalence, and local policies and resources 139 
that influence how early in the course of the disease TB and MDR-TB are detected by available diagnostics. In 140 
this study, the association between higher sputum bacterial load and MDR-TB was observed for TB retreatment 141 
patients with different treatment histories, including both patients that were failures on treatment as well as 142 
patients that were categorized as relapse or return after default patients and not on treatment at the time of 143 
diagnosis. If the association between higher sputum bacterial load and MDR-TB is also observed in other 144 
settings and patient populations, this would provide additional evidence that higher patient bacterial load leads to 145 
a higher probability for the development of MDR-TB. 146 
 147 
There were several potential limitations to this study. These data are from a single diagnostic laboratory, 148 
representing a limited geographical area. The number of case patients was relatively small, which resulted in 149 
relatively large confidence intervals for the various analyses; nevertheless, the 80 cases and 521 controls in the 150 
primary analysis provided 80% power to detect an odds ratio of 2 with 95% confidence, assuming 25-48% 151 
exposure in the control population. There are known weaknesses in the specimen collection and transport system 152 
for specimens sent to this lab in a resource-limited setting; however, our analyses indicated that these factors are 153 
unlikely to lead to systematic bias in the results. Bacterial viability remained high (94% of smear-positive 154 
diagnostic specimens were culture positive) and the culture contamination rate was low (2.1% of diagnostic 155 
specimens), as shown in Supplementary Figure 2. Also, in Cameroon, an estimated 38% of TB patients are HIV 156 
co-infected,2 but information about patient HIV-status is not routinely collected in the lab and was not included 157 
in this analysis. A recent meta-analysis found a marginal positive association between HIV-infection and MDR-158 
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TB globally (odds ratio 1.24; 95% CI 1.04-1.43) ;34 due to the relatively weak nature of this association, a 159 
similar trend in our setting is unlikely to significantly influence the association between MDR-TB and higher 160 
smear microscopy grade observed here, particularly since HIV-infected patients are more likely to produce 161 
paucibacillary sputum than HIV-negative patients. Also, in this analysis of laboratory data, patient clinical data 162 
such as radiography results, history of confirmed or potential exposure to MDR-TB, duration and type of 163 
symptoms at presentation, and co-morbidities such as diabetes and substance abuse were not evaluated. 164 
 165 
Geographical region was found to play a role in the current study. Systematic drug susceptibility testing of 166 
retreatment patients started in the Southwest region at the end of 2012, and the coverage during the study period 167 
was estimated as 21% of smear-positive retreatment patients; in contrast, for the other three regions the testing 168 
coverage was estimated as ≥75% of smear-positive patients in each region. It is possible that the relatively few 169 
specimens sent for testing from the Southwest were more likely to be from chronic patients that had survived for 170 
longer periods of time with drug-resistant disease prior to the start of systematic drug resistance testing. In spite 171 
of this effect of region on the prevalence of MDR-TB, there was a strong independent association of higher 172 
sputum bacterial load and MDR-TB across these four diverse regions of the country. 173 
 174 
In this analysis, we used graded smear microscopy results obtained after specimen concentration prior to 175 
inoculation for culture. The advantage of using the concentrated smear result for this analysis is that these results 176 
were generated by a single laboratory with good quality control systems in place, ensuring consistency among 177 
the semi-quantified results. It was not possible to perform an analysis using direct microscopy results from the 178 
peripheral laboratories because many sites either did not indicate the microscopy result on the request form or 179 
instead reported the direct microscopy result from a different specimen obtained from the patient than the one 180 
sent to the reference laboratory for testing. It will be important to analyze the association between MDR-TB and 181 
direct smear microscopy results in future work, as this information is of more practical significance for many TB 182 
programs. 183 
 184 
It will be of interest to assess whether the association between RR/MDR-TB and higher bacterial load that has 185 
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been observed here is also found to apply in other populations and/or settings, such as in patients who have 186 
never taken TB treatment or in places where laboratory testing for RR/MDR-TB is not yet widely available. This 187 
association may also be of use to ensure those with higher bacterial loads are prioritized for drug susceptibility 188 
testing.  189 
 190 
 
 
  191 
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Table 1. Characteristics of TB retreatment patients according to whether multidrug-resistant tuberculosis 
(MDR-TB) was diagnosed 
 
 
Characteristic 
All patients                                
(n=601) 
MDR-TB                            
(n=80) 
Not MDR-TB                            
(n=521) 
Age, years 36 (29-46) 36 (30-45) 36 (29-46) 
Female 206 (34) 34 (43) 172 (33) 
Region    
Littoral 406 (68) 55 (69) 351 (67) 
Northwest 115 (19) 11 (14) 104 (20) 
Southwest 14 (2) 7 (9) 7 (1) 
West 66 (11) 7 (9) 59 (11) 
Type of retreatment patient    
Relapse 412 (69) 41 (51) 371 (71) 
Return after default 105 (17) 7 (9) 98 (19) 
Treatment failure 84 (14) 32 (40) 52 (10) 
Smear positivity grade    
Negative 40 (7) 1 (1) 39 (8) 
Scanty 35 (6) 0 (0) 35 (7) 
1+ 77 (13) 2 (3) 75 (14) 
2+ 140 (23) 17 (21) 123 (24) 
3+ 309 (51) 60 (75) 249 (48) 
 
 
Data are median (IQR) or number (%). 
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Table 2. Associations of multidrug-resistant TB (MDR-TB) with age, sex, region, type of retreatment 
patient, and acid-fast bacilli smear-positivity 
 
 
Variable 
Unadjusted odds 
ratio (95% CI) P Value 
Adjusted odds 
ratio (95% CI)* P Value 
Age     
≤ 35 yrs 1.0  1.0  
>35 yrs 1.0 (0.6-1.6) 0.9 1.0 (0.6-1.7) 1.0 
Sex     
Male 1.0 1.0 1.0  
Female 1.5 (0.9-2.4) 0.1 1.5 (0.8-2.5) 0.2 
Region     
Littoral 1.0  1.0  
Northwest 0.7 (0.3-1.3) 0.3 0.9 (0.4-1.9) 0.8 
Southwest 6.4 (2.2-18.9) <0.001 5.8 (1.6- 20.9) 0.008 
West 0.8 (0.3-1.7) 0.5 0.6 (0.2-1.5) 0.3 
Type of retreatment patient     
Not failure 1.0  1.0  
Failure 6.0 (3.5-10.2) <0.001 10.2 (5.4-19.2) <0.001 
Smear-positivity grade     
Negative/Scanty/1+ 1.0  1.0  
2+ 6.9 (2.0-23.9) 0.003 10.9 (2.9-40.7) <0.001 
3+ 12.0 (3.7-38.8) <0.001 21.9 (6.2-76.8) <0.001 
 
 
 
*Adjusted for age, sex, region and type of patient. CI=confidence interval.  
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Table 3. Associations of multidrug-resistant TB (MDR-TB) with age, sex, region, type of retreatment 
patient, and time to detection of culture  
 
 
Variable 
Unadjusted odds 
ratio (95% CI) P Value 
Adjusted odds 
ratio (95% CI)* P Value 
Age     
≤ 35 yrs 1.0  1.0  
>35 yrs 1.2 (0.7-2.2) 0.6 1.1 (0.5-2.2) 0.9 
Sex     
Male 1.0  1.0  
Female 1.0 (0.5-1.9) 1.0 1.0 (0.5-2.1) 1.0 
Region     
Littoral 1.0  1.0  
Northwest 0.5 (0.2-1.2) 0.1 0.7 (0.3-1.9) 0.5 
Southwest 3.9 (0.9-17.0) 0.07 3.1 (0.5-18.8) 0.2 
West 0.5 (0.1-1.6) 0.2 0.3 (0.1-1.2) 0.1 
Type of retreatment patient     
Not failure 1.0  1.0  
Failure 22.8 (10.3-50.6) <0.001 22.9 (9.8-53.5) <0.001 
Time to detection, automated     
liquid culture 
    
> 160 hours 1.0  1.0  
≤ 160 hours 2.3 (1.2-4.4) 0.01 2.2 (1.1-4.7) 0.04 
 
 
 
*Adjusted for age, sex, region and type of patient. CI=confidence interval. 
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Figure 1. Study profile. 
AFB = Acid-fast bacilli. DST = Drug susceptibility testing. TTD = Time to detection of automated culture. 
 
Figure 2. Distribution of patients by MDR-TB status, sputum smear microscopy grade , and type of TB 
treatment history 
(A) Distribution of patients by MDR-TB status as a function of smear microscopy grade. The prevalence of 
MDR-TB among patients with smear grades of ≤1+, 2+ and 3+ was 1.0%, 7.0% and 15.7%, respectively. (B) 
Among all retreatment patients tested, 26% had a smear microscopy grade of ≤1+, 23% were graded as 2+, and 
51% as 3+. (C) Among patients identified as MDR-TB cases, 4% had a smear microscopy grade of ≤1+, 21% as 
2+, and 75% as 3+. An association between higher smear microscopy grade and MDR-TB was observed for 
retreatment patients with different treatment histories, including those classified as failure of treatment, as well 
as those classified as relapse or return after default and who were not on treatment at baseline diagnosis.  
 
 
